Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab
Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 201-209.e6
DOI: 10.1016/j.cgh.2025.04.025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Ben Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea. Hauptthemen laut MEDLINE: Crohn Disease, Drug Monitoring, Infliximab, Gastrointestinal Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celltrion Pharm Inc.
Abstract (Originalsprache)
BACKGROUND & AIMS: Proactive dosing based on therapeutic drug monitoring (TDM) of adalimumab is associated with higher rates of sustained corticosteroid-free clinical remission (SCFCR) in children with Crohn's disease (CD) than that with reactive TDM. We aimed to investigate whether proactive dosing of infliximab (IFX) based on TDM is associated with higher rates of endoscopic healing (EH) in pediatric patients with CD than that with clinically based dosing. METHODS: We conducted a non-blinded, randomized controlled trial of 112 biologic-naïve children with CD who had responded to IFX induction treatment at 4 centers in South Korea between July 2017 and November 2020. Patients were randomly assigned to receive dosing based on proactive TDM (proactive arm) or clinically based dosing (clinical arm). The primary endpoint was EH at week 54. RESULTS: The primary endpoint was achieved in 80.0% (40/50) of the proactive arm and 57.1% (28/49) of the clinical arm (P = .025). SCFCR was achieved in 69.6% (39/56) of the clinical arm and 89.3% (50/56) of the proactive arm at week 54 of treatment (P = .019). According to the multivariate logistic regression analysis, the intervention group (proactive arm vs clinical arm) was an independent factor associated with EH (odds ratio, 3.48; 95% confidence interval, 1.26-10.43; P = .019) and SCFCR (odds ratio, 5.50; 95% confidence interval, 1.72-21.61; P = .007). CONCLUSIONS: Dosing based on proactive TDM was superior to clinically based dosing in terms of EH in a randomized controlled trial of pediatric CD. Trial identifier: cris.nih.go.kr: KCT0005190.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea.
- Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pediatrics, Pusan National University Yangsan Hospital, College of Medicine, Pusan National University, Yangsan, Korea.
- Department of Pediatrics, School of Medicine, Inha University, Incheon, Korea.
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- Celltrion Pharm Inc
Zitieren
APA
Kang, B., Kim, E. S., Choi, S., Choe, B. H., Moon, J. S., Ko, J. S., Sohn, S., Lee, Y. J., Kwon, Y., Kim, M. J., Jeon, T. Y., Lee, S. M., Lee, S., Ju, Y., & Choe, Y. H. (2026). Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab. Clinical Gastroenterology and Hepatology, 24(1), 201-209.e6. https://doi.org/10.1016/j.cgh.2025.04.025
Vancouver
Kang B, Kim ES, Choi S, Choe BH, Moon JS, Ko JS, et al. Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab. Clinical Gastroenterology and Hepatology. 2026;24(1):201-209.e6. doi:10.1016/j.cgh.2025.04.025
BibTeX
@article{Kang2026,
author = {Kang, Ben and Kim, Eun Sil and Choi, Sujin and Choe, Byung-Ho and Moon, Jin Soo and Ko, Jae Sung and Sohn, Sangjun and Lee, Yeoun Joo and Kwon, Yiyoung and Kim, Mi Jin and Jeon, Tae Yeon and Lee, So Mi and Lee, Seunghyun and Ju, Youngcheol and Choe, Yon Ho},
title = {Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {1},
pages = {201--209.e6},
doi = {10.1016/j.cgh.2025.04.025}
}
EUVIMED